
Sware
Innovative regulatory compliance methodology, software tools and services for life sciences industry.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
* | $6.0m Valuation: $75.0m | Series B | |
Total Funding | 000k |
Related Content
Sware is a company that specializes in automating software validation processes for the life sciences industry. The company offers a platform called Res Q VLMS, which features pre-built compliance modules, intelligent workflow automation, structured risk assessments, and automated testing for over 30 systems. Sware's platform is designed to accelerate product releases, ensure compliance, and boost the bottom line for its clients. The company serves life sciences companies, including software developers for regulated applications, helping them transition to the regulated cloud. Sware's business model involves partnering closely with clients to provide end-to-end validation solutions, including a marketplace of ready-to-use templates, SOPs, test scripts, and workflows. The company generates revenue through its platform subscriptions and services. Sware recently raised $15 million in a Series A funding round to further transform the validation process for life sciences.
Keywords: software validation, life sciences, compliance modules, workflow automation, risk assessments, automated testing, regulated cloud, validation experts, Series A funding, Res Q VLMS.